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Fig. S1. Primary sequence of P. falciparum SERA5 and positions of proteolytic processing sites.  
Shown is the complete primary sequence of the P. falciparum 3D7 SERA5 gene product (PlasmoDB 
ID: PF3D7_0207600). Positions of cleavage by PfSUB1 are indicated in red (site 2 and site 3, as well 
as the allele-specific site 1; (Yeoh et al., 2007, Debrabant et al., 1992, Li et al., 2002)). The position of 
cleavage by protease X (Leu842), defined in this study as the P50C cleavage site, is also indicated. 
The sequence encompassed by the terminal P50 processing fragment is shaded in pink and the 
papain-like domain Ser558-Lys832 is underlined, with the predicted catalytic triad residues Ser596, 
His762 and Asn787 shaded in yellow and marked with asterisks. The N-terminal secretory signal 
peptide is shaded in grey. 
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Fig. S2. Degradation of  purified rSERA5-C is not the result of a contaminating protease activity.  
Purified recombinant proteins rSERA5-C and rSERA5-A (in 25 mM HEPES pH 7.4, 150 mM NaCl) were 
incubated either alone or as a mixture containing approximately equivalent amounts (~2 g) of the 
purified proteins, and sampled either immediately (start) or after 4 h at 37oC for analysis by SDS 
PAGE and Coomassie staining. The rSERA5-C underwent extensive degradation over the period of 
the incubation (compare the 1st and 4th tracks from the left), whereas rSERA5-A was essentially 
stable (compare the 3rd and 6th tracks from the left). The SERA5-A also remained stable in the mixed 
samples (compare the 2nd and 5th tracks), indicating that the rSERA5-C preparation does not contain 
a protease that is capable of degrading rSERA5-A in trans. Note that the batches of both proteins 
used for this experiment displayed more degradation immediately following purification than the 
(different) batches used for the experiment presented in Fig. 2B of the main manuscript. 
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Fig. S3. Cleavage of TACE substrate IV by rSERA5-C takes place predominantly at the Arg-Ser bond.  
A. Reversed-phase (RP)-HPLC elution chromatograms of mock-digested and rSERA5-C-digested TACE 
substrate IV (Abz-LAQAVRSSSR-Dpa).  Digestions were carried out for 4 h at 37oC in 100 l 25 mM 
Bis-Tris buffer pH 6.5 containing 1 mM EDTA, 10 mM DTT and 0.05% (w/v) Tween 20, using a 
substrate concentration of 10 M and either no protein additions (mock digested) or 1 g purified 
rSERA5-C. Digests were then fractionated by RP-HPLC chromatography on a Vydac 4.6 mm  25 cm 
C18 reversed-phase column, eluted at 1 ml min
-1 with a 18-54% (v/v) gradient of acetonitrile in 0.1% 
TFA over 15 min, with continuous monitoring of eluted components using a Jasco FP-920 
fluorescence detector (ex 320 nm, em 420 nm). RP-HPLC-analysis of undigested substrate, or 
substrate incubated under similar conditions with purified rSERA5wt or rSERA5-A, produced elution 
profiles identical to that of the mock-digested substrate in the top panel (not shown). The intact 
substrate eluted as a weakly fluorescent peak at 11.2 min, whilst in the fully digested samples a 
major fluorescent peak appeared at 7.8 min. Identities of the indicated peaks, including the 
predicted and measured masses of the major digestion product as determined by electrospray mass 
spectrometry, are shown. The minor fluorescent digestion product eluting at 7.02 min could not be 
identified, but presumably is a result of less frequent cleavage at another position in the substrate 
peptide backbone. 
B. Schematic structure of Abz-LAQAVRSSSR-Dpa (Jin et al., 2002). In the intact peptide the 
fluorescence of the N-terminal donor Abz group is quenched by the accepting Dpa group. Cleavage 
at any point in the peptide backbone produces a highly fluorescent N-terminal product. Calculated 
molecular masses of the intact substrate and the Abz-LAQAVR major cleavage product obtained in 
this study are indicated. 
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Fig. S4. Cleavage of TACE substrate IV by rSERA5-C displays Michaelis-Menten kinetics. 
A. Extended progress curve showing hydrolysis of Abz-LAQAVRSSSR-Dpa by rSERA5-C. Substrate 
(1.25 M) in 100 l 25 mM Bis-Tris buffer pH 6.5 containing 1 mM EDTA, 10 mM DTT and 0.05% 
(w/v) Tween 20, was supplemented with 1 g purified rSERA5-C and incubated at 21oC. Increase in 
fluorescence was continuously monitored with time (at 5 min intervals) as described previously 
(Blackman et al., 2002) using a Cary Eclipse fluorescence spectrophotometer (Varian) equipped with 
a 96-well microplate reader accessory (ex 320 nm, em 420 nm).  The curve displayed represents 
individual reads from a single well of a kinetic assay; readings taken from triplicate wells in the same 
experiments showed no more than 4% variation from the plot shown at individual time-points.  
B. Plot of initial hydrolysis rate (V) against substrate concentration. Initial rates were calculated 
under conditions in which <10% of substrate had been hydrolysed, based on progress curves such as 
that shown in (A). 
C. Lineweaver-Burk transformation of the data shown in (B). The line of best fit was calculated by  
linear regression in Microsoft Excel. The intersect of the plot with the y-axis provides a measure of 
Vmax (the hydrolysis rate under conditions of substrate saturation, calculated as 8.8 RFU min
-1), whilst 
the slope of the plot equates to Km/Vmax. The Km value (the substrate concentration at which the 
hydrolysis rate is equal to half of Vmax) is calculated in this experiment as 11.3 M.  
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Fig. S5. Genomic integration by single-crossover homologous recombination of constructs targeting 
the SERA5 locus. 
A. Southern blot analysis of genomic DNA isolated from uncloned parasite cultures transfected with 
pHH1SERA5chimWT or pHH1SERA5chimS596A (3 independently-transfected cultures in each case, 
labelled 1-3)  at drug-selection cycle 0 or cycle 4, compared with DNA from the parental 3D7 clone 
(control). By cycle 4, almost quantitative integration of the constructs was evident. Positions of 
migration of the 8.8 kb signal diagnostic of the endogenous SERA5 locus, and the 4.4 and 5.7 kb 
signals characteristic of the integrant SERA5 locus (see Fig. 3A, main manuscript) are indicated. The 
probe used for Southern analysis also detected an ~ 1 kb EcoRV fragment (indicated) derived from 
the input integration construct. 
B. Southern blot analysis of chimS596A and chimWT clones obtained by limiting dilution, compared 
with the uncloned chimS596A transfection culture 2 (from drug cycle 0 and 4). All isolated clones 
except clone i show loss of the endogenous fragment signal at 8.8 kb  and display the 4.4 and 5.7 kb 
bands characteristic of the integrant SERA5 locus. In the examples shown, residual input integration 
construct was also detectable in DNA from the chimWT clones; this was an occasional feature of 
clones derived from all transfection experiments (not shown). 
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Fig. S6. Reverse transcriptase-PCR analysis detects mRNA expression only from the chimeric SERA5 
ORF produced following genomic integration of targeting constructs.  
A. RT-PCR was performed using total RNA purified from 3D7 parental P. falciparum, or various drug-
resistant parasite clones obtained following transfection of the constructs described in Fig. 3A of the 
main manuscript. Primer pairs used (indicated) were designed to detect either mRNA transcribed 
from the chimeric SERA5 locus resulting from the integration event depicted in Fig. 3A (primers +27 
plus -11), or an mRNA transcript similar to that from the endogenous gene, which could potentially 
arise by  extended splicing of run-through transcript of the modified locus (primers +27 plus -25). 
Parasite clones used as a source of RNA were: clone i (transfected with pHH1SERA5chimWT but 
displaying no integration of this construct; see Fig. S5B above); clone h (chimWT); and clone d 
(chimS596A). The results showed that primers +27 plus -25 produced an RT-PCR product only from 
parasites harbouring an unmodified SERA5 locus, indicating that the unlikely possibility of run-
through transcription and splicing to produce a wild-type mature SERA5 mRNA transcript did not 
take place in parasites harbouring the chimeric SERA5 locus. As expected, primers +27 plus -11 
amplified a product only from the clones that had integrated the pHH1-based constructs. PCR 
reactions performed without reverse transcriptase (RT) usually gave no product.  Where trace 
product is evident, this is likely due to the fact that the RNA used in these experiments was not 
DNase-treated before the RT reaction. However, because of the presence of intron sequence the 
products derived from these trace amounts of genomic DNA template migrate at a higher molecular 
weight than the mRNA-derived products. M, molecular mass marker DNA ladder (SmartLadder, 
Eurogentec). The primer pairs used for RT-PCR, and the predicted sizes of the resulting amplicons 
(which lack the introns present in the genomic sequence) are indicated. 
B. RT-PCR products obtained from parasite clones h (chimWT) and d (chimS596A) were incubated in 
the absence  or presence of the restriction enzyme BstUI. The restriction fragment pattern obtained 
is consistent with the presence of an additional BstUI site in the transcript arising from the 
chimS596A gene compared to that from the chimWT gene (see Experimental Procedures), 
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confirming preservation of the mutation at the mRNA level. M, 100 bp molecular mass marker DNA 
ladder. 
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Fig. S7. Predicted structural consequences of substituting the SERA5 Ser596 with Arg. 
Depicted are views facing the ‘active site cleft’ of the P. falciparum SERA5 papain-like domain (PDB 
ID: 2WBF) represented as a green molecular surface, with Ser596 shown in red. The wild-type 
protein is depicted on the left-hand side, whilst the predicted structure resulting from substitution of 
Ser596 with Arg  is shown on the right. The much larger Arg side chain (shown as blue sticks with its 
surface as a blue mesh) is predicted to extend into the cleft and interfere with binding of putative 
client molecules. The figures were prepared with PyMol (http://pymol.org/). 
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Fig. S8. Introduction of a mini TAP tag into the endogenous P. falciparum SERA5 gene. 
Schematic depiction of the primary sequence modifications made in introducing the mini TAP tag 
into the SERA5 gene using transfection construct pHH1SERA5chimP6mTAP. The modification 
replaces the bulk of the P6 encoding region (see Fig. 1B of the main manuscript) with the mini TAP 
tag sequence. The wild type 3D7 SERA5 sequence (Lys836-Thr900) is shown aligned with the 
sequence introduced by integration of pHH1SERA5chimP6mTAP. Non-wild type residues 
introduced are shown in red, with the major elements of this underlined and indicated. Note that 
introduction of the mini TAP tag sequence modifies the PfSUB1 site 2 cleavage site. Whether this 
affects PfSUB1-mediated cleavage at his position was not examined in this study. 
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Table S1. Peptide substrates used to examine the protease activity of purified native P. falciparum 
P50 and recombinant SERA5 (rSERAwt, rSERA5-A and rSERA5-C). 
Substrate name Substrate structure Cleavage determination
j,k
 
PfSUB2 PD NH2-HEENNKHKLNKKNSSNYKNDKSLDEC-OH
a
 RP-HPLC 
PfSUB3 NH2-RNKLYLKKKKECSNYNTSNDGHGHC-OH
a
 RP-HPLC 
ST-24 NH2-IKSKKTYINSNISNKWKKKSRYLHC-OH
a
 RP-HPLC 
PfAMA1stub NH2-SNNEVVVKEEYKDEYADIPEHKPTC-OH
a
 RP-HPLC 
Chymotrypsin substrate Suc-AAPF-AMC
b,c,d,e,f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Chymotrypsin substrate Suc-LLVY-AMC
b,c,d,e,f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
pepF1-6R Ac-C(Rho)LVSADNIDIC(Rho)-OH
d,e,i
 Fluorometric  (Ex 552, Em 580 nm) 
SERA5st1F-6R Ac-C(Rho)IKAETEDDC(Rho)-OH
d,i
 Fluorometric  (Ex 552, Em 580 nm) 
SERA5st2F-6R Ac-C(Rho)IFGQDTAGC(Rho)-OH
d,i
 Fluorometric  (Ex 552, Em 580 nm) 
SERA4st1F-6R Ac-C(Rho)ITAQDDEEC(Rho)-OH
e,i
 Fluorometric  (Ex 552, Em 580 nm) 
SERA4st1F-6R12 Ac-C(Rho)KITAQDDEESC(Rho)-OH
e,i
 Fluorometric  (Ex 552, Em 580 nm) 
SERA4st1F-6RprimeS Ac-C(Rho)ITAQSDEEC(Rho)-OH
e,i
 Fluorometric  (Ex 552, Em 580 nm) 
Papain substrate N-Benzoyl-L-Arg-AMC
d
 Fluorometric (Ex 360 nm, Em 460 nm) 
Caspase-3 substrate Ac-DEVD-AMC
d
 Fluorometric (Ex 360 nm, Em 460 nm) 
Caspase-3 substrate Ac-DMQD-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Caspase-6 substrate Ac-VEID-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Caspase-1 substrate Ac-WEHD-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Proteasome substrate Z-GGL-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Factor IX/Xa substrate Boc-IEGR-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
SUB1trunc substrate Ac-KITAQ-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Furin substrate Boc-RVRR-AMC
d,f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
SUB2trunc substrate Z-GML-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
GR-AMC NH2-GR-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Cathepsin K substrate Z-LR-AMC
f,g,h
 Fluorometric (Ex 360 nm, Em 460 nm) 
Cathepsin B substrate V Abz-GIVRAK(Dnp)-OH
f,g,h
 Fluorometric (Ex 320 nm, Em 420 nm) 
-secretase substrate VII Abz-VKMDAE-EDDnp
f,g,h
 Fluorometric (Ex 320 nm, Em 420 nm) 
TACE substrate IV Abz-LAQAVRSSSR-Dpa
f,g,h
 Fluorometric (Ex 320 nm, Em 420 nm) 
 
a-hAssay buffer conditions: a25 mM HEPES pH 6.5, 12.5 mM CHAPS, 10 mM CaCl2; 
b25 mM HEPES pH 
6.5, 1 mM DTT;  c25 mM HEPES pH 6.5, 1 mM DTT, 20 mM CHAPS, 1.5 mM CaCl2; 
d50 mM HEPES pH 
6.5, 25 mM CHAPS, 10 mM CaCl2, 1 mM DTT; 
e25 mM HEPES pH 7.4, 25 mM CHAPS, 12 mM CaCl2; 
f25 
mM HEPES pH 7.4, 15 mM CaCl2, 2 mM DTT;  
g25 mM Bis-Tris pH 6.5, 1 mM EDTA, 5 mM DTT; h 50 
mM sodium acetate pH 5.5, 5 mM MgCl2, 5 mM DTT. 
i C(Rho), terminal Cys residues labelled with 6-iodoacetamido tetramethylrhodamine, produced as 
described previously (Blackman et al., 2002, Koussis et al., 2009, Yeoh et al., 2007, Withers-Martinez 
et al., 2012). 
j Peptide hydrolysis was assessed by fractionation of digestion reactions on a Vydac 4.6 mm  25 cm 
C18 reversed-phase column, eluted at 1 ml min
-1 with a 0-55% (v/v) gradient of acetonitrile in 0.1% 
(v/v) TFA over 60 min. 
k Fluorogenic peptide hydrolysis was monitored continuously at room temperature as previously 
described (Blackman et al., 2002) using a Varian Cary Eclipse fluorescence spectrophotometer by 
measuring the increase in fluorescence of AMC or Abz using the indicated excitation and emission 
wavelengths. 
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Table S2. Oligonucleotide primers used in this study.  
Primer name Sequence (5’-3’) 
+S5endogHpaI GGGGTTAACGTACGGGAACAGTTAGAGGAG 
-S5endogClaI TATTATCGATAGATTCTGTTAATTTATATTCAG 
+S5Seq1021 GCGATATTCCGGAAAAATGCG 
-S5stopXhoI ACTCGAGCTACACGTAGCAGAAATAGCATTC 
-S5_StoA_BstUI CGCAAAAATCCACGCGGTATCGCAGTT 
+S5_StoA_BstUI AACTGCGATACCGCGTGGATTTTTGCG 
-S5XbaIKO TAAGAAACCATAATTCTAGATAATCTGCAGAA 
+S5XbaIKO TTCTGCAGATTATCTAGAATTATGGTTTCTTA 
-S5StoR_MluI CTCGCAAAAATCCAACGCGTATCGCAGTTG 
+S5StoR_MluI CAACTGCGATACGCGTTGGATTTTTGCGAG 
+S5Seq2021 GAAAGTGGGCGAACAGTG 
-1longHS GAACGTCGTAAGGGTAGCCCATGGCATAGTCCGGGACGTCATAGGGATAGCCCGCATAGTCAGGA
ACATCGTAAGGGTACTCCGGGCTCGCCTTCAGATAATAATC 
+2longHS TGGGCTACCCTTACGACGTTCCAGATTACGCTAGCGCTTGGAGCCACCCGCAGTTCGAGAAACTTGA
GAATTTGTATTTTCAGGGTACAGCGGGTAGCGGCCAGA 
-29_S5stopXhoI GGGTACTCGAGCTACACGTAGCA 
+BamHImelit CCCGGATCCATGAAATTCTTAGTCAACGTTGCC 
-melitSERA5 GCCGGTCTGGCTTTCGCCGGTGGCATAGATGTAAGAAAT 
-S5ENDHindIII CCCAAGCTTTCACACGTAGCAGAAATAGCATTC 
-S5_StoC CGCAAAAATCCAGCAGGTATCGCAGTT 
+ S5_StoC AACTGCGATACCTGCTGGATTTTTGCG 
+27 CAATATCATTTGAATCAAACAGTGGT 
-11 CTTTGCCATCCAGGCTGTTC 
-25 CCATTGGACTAGAACCTTCAT 
b ACTACGCAATAGGATCAGAC 
Q+SERA1
a
 GCGTATCAAGAGATACTCTAGATAAGGATAG 
Q-SERA1
 a
 CTGATATCTACTTTGTTATTTGTAACTCCTG 
Q+SERA2
 a
 TTTATATTGTATCTTCAACATGATTTGATAAC 
Q-SERA2
 a
 TAAATCTACTTGACCTGGAGCTATCC 
Q+SERA3
 a
 AAGTATGTTAAAGAATAAATGTGAATCTGG 
Q-SERA3
 a
 TCTTCAGATTTTTGTGGAGTAGCAG 
Q+SERA4
 a
 TGTGAAAGATGACACAAAAAAATTTG 
Q-SERA4
 a
 ATTTCATCCACATCTTGTTCCTTG 
Q+SERA5
 a
 TATATGTGAAACTGGAAAAAACTTCAAG 
Q-SERA5
 a
 ACTTTCTTACATCAACTTTGTTATTTTCAG 
Q+SERA6
 a
 GTTGAGCACAAGGGGAACTTC 
Q-SERA6
 a
 CTTACATCCGAATCTTCACTCTTTG 
Q+SERA7
 a
 GGTCCATCCGATTTAATAGATATAAATG 
Q-SERA7
 a
 TCGATGTTTGTTGGTTTAGAATCC 
Q+SERA8
 a
 CCTTGTACACAAAACCATGAAAGC 
Q-SERA8
 a
 CGTGTAAACCCAACGTATGCC 
Q+SERA9
 a
 AAGGATCAACTGAATATGAAGAAAGTG 
Q-SERA9
 a
 TCTAATGTACTATTTAAGTCTTCAAAACTTATC 
Q+tubulin
 a
 ATGAGCATGGAATAGATCCAAGTG 
Q-tubulin
 a
 CCAGGTTCCAAGTCCATCAATATAG 
Q+AMA1
 a
 CCTCCAACAGAACCTCTTATGTCAC 
Q-AMA1
 a
 TCCTGCATGTCTTGAACATAAAGTC 
Q+MSP1
 a
 CTACGAAATCTGTTCAAATACCAAAAG 
Q-MSP1
 a
 TTCTTTAGTATGAGGATTCATTAAATCAC 
a
 All primers with names beginning with ‘Q’ were used for the RTqPCR analyses. 
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